Radionuclide therapy using 177Lu-PSMA: a pilot study in men with castrate-resistant prostate cancer (LuPSMA trial)
Phase 1
Completed
- Conditions
- castrate-resistant prostate cancer
- Registration Number
- ACTRN12618001552279
- Lead Sponsor
- St Vincent's Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 15
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie 177Lu-PSMA efficacy in castrate-resistant prostate cancer?
How does 177Lu-PSMA compare to standard-of-care treatments for CRPC in terms of survival and toxicity?
Which biomarkers are associated with response to 177Lu-PSMA therapy in metastatic castrate-resistant prostate cancer?
What are the potential adverse events and management strategies for 177Lu-PSMA radionuclide therapy?
Are there combination approaches or competitor drugs that enhance 177Lu-PSMA outcomes in CRPC?